[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345074-105":59,"doc-detail-345074-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nous-209-off-the-shelf-immunotherapy-has-the-potential-to-hit-primary-and-metachronous-colorectal-and-urothelial-cancers-in-lynch-syndrome-research-summary","NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome - Research Summary","","Lynch syndrome is driven by inherited defects in DNA mismatch repair and leads to microsatellite instability cancers that generate shared neoantigens, creating an opportunity for targeted immunotherapy. NOUS-209 is a heterologous prime-boost cancer vaccine using viral vectors to deliver 209 shared frameshift-mutation (FSM) neoantigen peptides derived from tumors with microsatellite instability. The study examines whether these NOUS-209 targeted FSMs persist in both primary and metachronous Lynch syndrome–associated cancers. Whole-exome sequencing of 73 tumors from 58 confirmed Lynch syndrome patients shows similar FSM burdens across primary and metachronous colorectal and urothelial cancers. Matched analyses indicate immune editing, with highly immunogenic predicted neoepitopes selectively lost in metachronous tumors, while lower-immunogenicity FSMs are retained. Subsequent primary cancers acquire new FSMs encoding neoantigens with strong predicted HLA-binding affinity, supporting immune interception. Overall findings suggest NOUS-209 immunotherapy may extend beyond colorectal cancer to help prevent both primary and metachronous Lynch syndrome–associated malignancies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nous-209-off-the-shelf-immunotherapy-has-the-potential-to-hit-primary-and-metachronous-colorectal-and-urothelial-cancers-in-lynch-syndrome-research-summary/345074/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nous-209-off-the-shelf-immunotherapy-has-the-potential-to-hit-primary-and-metachronous-colorectal-and-urothelial-cancers-in-lynch-syndrome-research-summary/345074.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is NOUS-209 and how is it designed to target Lynch syndrome cancers?","Question",{"text":113,"@type":114},"NOUS-209 is a heterologous prime-boost cancer vaccine that uses viral vectors to encode 209 shared neoantigen peptides derived from frameshift mutations found in microsatellite-instable tumors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What did whole-exome sequencing show about targeted FSMs in primary versus metachronous cancers?",{"text":118,"@type":114},"Across colorectal and urothelial cancers, the study observed similar FSM burdens in both primary and metachronous tumors, using sequencing of 73 tumors from 58 Lynch syndrome patients.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports immune editing in metachronous tumors?",{"text":122,"@type":114},"In matched primary–metachronous tumor pairs, FSMs predicted to form highly immunogenic neoepitopes were selectively lost in metachronous tumors, while lower-immunogenicity FSMs were retained.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345074,1790468466,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome  \nLorenzo De Marco1, Elisa Micarelli1, Joni Panula2,3,4, Jussi Nikkola2,4,5, Lauri Moilanen6, Matti Annala2, Jouni Hrknen6, Kalle E. Hokkanen2, Anna Morena D’Alise1, Kirsi Pylvninen7, Pivi T. Peltomki8,9, Maarit Ahtiainen10, Jan Bhm6, Jukka-Pekka Mecklin11,12, Elisa Scarselli1, and Toni T. Seppl2,4,13,14  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Lynch syndrome is characterized by the development of microsatellite-instable cancers that share neoantigens, offering an opportunity for targeted immunotherapy. NOUS-209 is a heterologous prime-boost cancer vaccine in clinical development, employing viral vectors encoding 209 shared neoantigen peptides derived from frameshift mutations (FSM) commonly found in microsatellite-instable tumors. In this study, we investigated the presence and dynamics of NOUS-209 targeted FSMs in both primary and metachronous Lynch syndrome–associated cancers. Whole-exome sequencing was performed for 73 tumors, including 58 colorectal cancers and 15 urothelial cancers, from 58 individuals with confirmed Lynch syndrome. A median of 57 FSMs per colorectal cancer and 24 FSMs per urothelial cancer were observed, with similar FSM burdens in both primary and metachronous tumors. Analysis of nine matched\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | primary–metachronous tumor pairs revealed evidence of immune editing: FSMs predicted to encode highly immunogenic neoepitopes were selectively lost in metachronous tumors, whereas those with lower predicted immunogenicity were retained. Importantly, all subsequent primary cancers acquired novel FSMs encoding neoantigens with strong predicted HLAbinding affinity, supporting the rationale for NOUS-209– mediated immune interception. These findings demonstrated that NOUS-209 FSMs are present in both colorectal cancersand urothelial cancers in Lynch syndrome, expanding the therapeutic potential of NOUS-209 beyond colorectal cancer. Moreover, the emergence of novel targetable FSMs in metachronous tumors suggests that NOUS-209 immunotherapy may be effective in the prevention of both primary and metachronous Lynch syndrome–associated cancers. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nLynch syndrome is one of the most common hereditary cancer predisposition conditions caused by a heterozygous germline pathogenic variant in one of the DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, or PMS2) or by a deletion in EPCAM, which induces methylation of the adjacent MSH2 promoter, thereby impairing MMR function (1) . Lynch syndrome confers the most pronounced risk for colorectal and endometrial cancers but also increases the risk for other malignancies, including urothelial cancer (2) .  \nMMR-proficient cells become MMR deficient by acquiring a second hit, often ","cbCaigzR3BxLTX8V","https://ap.wps.com/l/cbCaigzR3BxLTX8V","pdf",1845704,12,"English","# Introduction\n## Lynch syndrome and microsatellite instability\n## MMR deficiency and frameshift neoantigens\n# Study rationale and design\n## NOUS-209 vaccine concept\n## Targeted FSM dynamics in primary vs metachronous cancers\n# Key findings\n## FSM burdens across cancer types\n## Evidence of immune editing\n## Implications for immune interception and prevention","[{\"question\":\"What is NOUS-209 and how is it designed to target Lynch syndrome cancers?\",\"answer\":\"NOUS-209 is a heterologous prime-boost cancer vaccine that uses viral vectors to encode 209 shared neoantigen peptides derived from frameshift mutations found in microsatellite-instable tumors.\"},{\"question\":\"What did whole-exome sequencing show about targeted FSMs in primary versus metachronous cancers?\",\"answer\":\"Across colorectal and urothelial cancers, the study observed similar FSM burdens in both primary and metachronous tumors, using sequencing of 73 tumors from 58 Lynch syndrome patients.\"},{\"question\":\"What evidence supports immune editing in metachronous tumors?\",\"answer\":\"In matched primary–metachronous tumor pairs, FSMs predicted to form highly immunogenic neoepitopes were selectively lost in metachronous tumors, while lower-immunogenicity FSMs were retained.\"}]","NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome - Research Summary | PDF",1790056425,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3239ab5fdf7bbb7e2582353d7d0b6cb.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c89cb8d4cf2c5b2febea380c9793218c.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7f3c73c44301e6eb625516b1de8a971.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4f8cdc7d602190d238652fd960d9450.webp",980,1311]